JAK1 selective inhibitors
AssigneeAstaZeneca AB
InventorsKarl Magnus Nilsson, Annika Birgitta Margareta Åstrand, Anna Ingrid Kristina Berggren, Johan R. Johansson, Matti Juhani Lepistö, Sameer Pralhad Kawatkar, Qibin Su, Jason Grant Kettle
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8 have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.
Claims24
A method of treating a JAK1-related disorder in a subject comprising administering a therapeutically effective amount of the compound (R)-N-(3-(5-fluoro-2-(2-fluoro-3-(methylsulfonyl)phenylamino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide, or a pharmaceutically acceptable salt thereof.
A method of treating a JAK1-related disorder in a subject comprising administering a pharmaceutical composition which includes:
- a therapeutically effective amount of the compound (R)-N-(3-(5-fluoro-2-(2-fluoro-3-(methylsulfonyl)phenylamino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide, or a pharmaceutically acceptable salt thereof;
- and a pharmaceutically acceptable diluent, excipient, or carrier.
A method of treating a JAK1-related disorder in a subject comprising administering a therapeutically effective amount of the compound (R)-N-(3-(5-fluoro-2-(2-fluoro-3-(methylsulfonyl)phenylamino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide.
A method of treating a JAK1-related disorder in a subject comprising administering a pharmaceutical composition which includes:
- a therapeutically effective amount of the compound (R)-N-(3-(5-fluoro-2-(2-fluoro-3-(methylsulfonyl)phenylamino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide;
- and a pharmaceutically acceptable diluent, excipient, or carrier.
A method of treating a JAK1-related disorder in a subject comprising administering a therapeutically effective amount of a pharmaceutically acceptable salt of the compound (R)-N-(3-(5-fluoro-2-(2-fluoro-3-(methylsulfonyl)phenylamino)pyrimidin-4-yl)-1H -indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide.
A method of treating a JAK1-related disorder in a subject comprising administering a pharmaceutical composition which includes:
- a therapeutically effective amount of a pharmaceutically acceptable salt of the compound (R)-N-(3-(5-fluoro-2-(2-fluoro-3-(methylsulfonyl)phenylamino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin -1-yl)propanamide;
- and a pharmaceutically acceptable diluent, excipient, or carrier.
Dependencies are inferred from the claim text.